Use of sirolimus after kidney transplantation is associated with a reduced risk of malignancy but an increased overall risk of death, according to findings of a systematic review and meta-analysis. Knoll and colleagues analysed data from 5,876 participants of randomized controlled trials that compared immunosuppressive regimens with and without sirolimus. Sirolimus use was associated with a 40% reduction in the risk of malignancy and a 56% reduction in the risk of nonmelanoma skin cancer, but an increased risk of death (HR 1.43, 95% CI 1.21–1.71) compared with controls.
References
Knoll, G. A. et al. Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data. BMJ 349, g6679 (2014)
Rights and permissions
About this article
Cite this article
Sirolimus: effects on malignancy and survival. Nat Rev Nephrol 11, 64 (2015). https://doi.org/10.1038/nrneph.2014.235
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2014.235